Clinical trials: Fibrosis Lung
Idiopathic Pulmonary Fibrosis
Daoyin Technique for Improving Exercise Endurance in IPF
This study is based on the previously constructed digital rehabilitation management platform, scientifically evaluating the clinical efficacy of guided technology in improving IPF exercise endurance, and forming high-quality…
- Trial name
- NCT07019714
- Testing
- Daoyin Technique, Routine Comprehensive Training
- Where
- 3 sites in China
- Volunteers
- 236 people
- Sponsor
- Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Kidney Transplant, Kidney Transplantation
Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients
There is a need to develop blood and/or urine tests that will help to detect early signs of rejection in people who have had kidney transplant.
- Trial name
- PROGENI-KI (NCT01289717)
- Where
- 5 sites in United States
- Volunteers
- 307 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
Combined Growth Differentiation Factor-15 (GDF-15) and Lung Ultrasound for ILD Screening in Rheumatoid Arthritis and Systemic Sclerosis
The goal of this observational study is to detect the lung affection in patients with Rheumatoid Arthritis(RA) or Systemic sclerosis (SSc) before appearance of symptoms(Subclinical) using combined diagnostic modalities which are…
- Conditions
- Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Interstitial Lung Disease (ILD)
- Trial name
- NCT07839221
- Testing
- Lung ultrasound, GDF-15 level (ELISA), CT scan
- Volunteers
- 110 people
- Sponsor
- Assiut University
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part.
- Trial name
- NCT06360094
- Testing
- BI 1839100
- Where
- 99 sites in United States, Australia and 22 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis (IPF)
IPF Longitudinal Natural History Study
This is a longitudinal observational cohort study of patients with idiopathic pulmonary fibrosis (IPF) conducted within the Assiut University IPF Research Program between 2022 and 2026.
- Trial name
- NCT07560189
- Where
- Egypt
- Volunteers
- 1,423 people
- Sponsor
- Assiut University
Musculoskeletal Infection, Chronic Rhinosinusitis (Diagnosis)
Establishing Personalized Phage Therapy and Its Comparative Cost in Difficult-to-treat Infections (EPHICACI)
EPHICACI is a multicenter, prospective study that continues and expands the monocentric PHAGEFORCE registry initiated at UZ Leuven.
- Conditions
- Musculoskeletal Infection, Chronic Rhinosinusitis (Diagnosis), Persistent Bacteremia, Pulmonary Infection
- Trial name
- EPHICACI (NCT06368388)
- Testing
- Prospective data collection phage therapy, Prospective data collection standard-of-care
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pulmonary Fibrosis
Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.
- Trial name
- NCT07229716
- Testing
- HRS-9813 Capsule, Nintedanib Soft Capsules, Pirfenidone Tablets
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis (IPF)
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone…
- Trial name
- ARGiNAUT (NCT07652658)
- Testing
- AZD8965 low dose, AZD8965 medium dose, AZD8965 high dose
- Where
- 195 sites in United States, Argentina and 21 more
- Volunteers
- 359 people
- Sponsor
- AstraZeneca
Interstitial Lung Disease, COPD
Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as…
- Conditions
- Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- GUARDIANLUNG (NCT04930289)
- Testing
- LungGuard, BAROGuard
- Where
- 15 sites in United States, Belgium
- Volunteers
- 3,500 people
- Sponsor
- Paragonix Technologies
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time.
- Trial name
- NCT06317285
- Testing
- GSK3915393
- Where
- 56 sites in United States, Argentina and 8 more
- Volunteers
- 158 people
- Sponsor
- GlaxoSmithKline
Covid19, Sars-CoV-2 Infection
Post Acute Sequelae of COVID-19
COVID-19, a novel coronavirus, has caused widespread mortality and morbidity since it emerged in 2019. There is ongoing research and growing literature describing severe acute respiratory syndrome (SARS-COV-2).
- Conditions
- Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- PASC (NCT04964115)
- Testing
- Cohort study
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Fibrosis, Interstitial Lung Disease
Pulmonary Fibrosis Foundation Community Registry
Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members.
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Lung Fibrosis, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT05382572
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Pulmonary Fibrosis Foundation
Pulmonary Fibrosis
The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis Who Take Nintedanib
The aim of this study is to describe patients' satisfaction with Patient Support Program (Balance Program), Quality of Life and depression symptoms, dosing pattern, disease symptoms, adverse events and nintedanib discontinuation…
- Trial name
- NCT06912659
- Where
- Spain
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Adjustment Disorder
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to…
- Trial name
- NCT07002034
- Testing
- RE104 for Injection
- Where
- 32 sites in United States
- Volunteers
- 100 people
- Sponsor
- Reunion Neuroscience Inc
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
The goal of this observational study is to learn about the inspiratory flow rate capability in patients with pulmonary fibrosis (IPF or PPF) when using inhaler devices with different resistances.
- Trial name
- NCT07820254
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Cystic Fibrosis
Pulmonary Vascular Disease in CF
In this project, the investigators seek to understand the role of endothelial cells in Cystic Fibrosis (CF) lung disease. This objective will be achieved by conducting a cross sectional clinical study to define the morphology of…
- Trial name
- CF (NCT04549077)
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
This trial is a randomized, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of inhaled Nintedanib Dry Powder Inhalation (DPI) in adults with idiopathic pulmonary fibrosis (IPF).
- Trial name
- INFLO-2 (NCT07679893)
- Testing
- Nintedanib Dry Powder Inhalation
- Where
- Canada
- Volunteers
- 153 people
- Sponsor
- Mannkind Corporation
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
This pilot randomized controlled trial evaluates the feasibility, acceptability, and accessibility of SUPPORT-T, a digitally delivered palliative care intervention for patients with Progressive Pulmonary Fibrosis (PPF) and their…
- Trial name
- NCT07269262
- Testing
- SUPPORT-T Educational Intervention
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Medical University of South Carolina
Pulmonary Hypertension, Interstitial Lung Disease
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases
- Trial name
- NCT07816185
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 3 sites in United States
- Volunteers
- 376 people
- Sponsor
- Pulmovant, Inc.
Pulmonary Hypertension, Interstitial Lung Disease
A Study of Mosliciguat in PH-ILD
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
- Trial name
- PHocus (NCT06635850)
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 85 sites in United States, Argentina and 18 more
- Volunteers
- 135 people
- Sponsor
- Pulmovant, Inc.